ArticleJACC. Case reports2025
Transcatheter Aortic Valve Replacement and Percutaneous Coronary Intervention After Ozaki Procedure in Alagille Syndrome.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Ozaki procedure is a novel therapeutic alternative to aortic valve replacement that involves excision of the native valve and replacement with neo-leaflets trimmed from the patient's pericardium. CASE SUMMARY: A 35-year-old man with Alagille syndrome and severe symptomatic stenosis of his neo-aortic valve was admitted 4 years after an Ozaki procedure. Given his high risk of redo surgery and nonsusceptibility to oral anticoagulation, valve-in-valve transcatheter aortic valve replacement (TAVR) with RESILIA tissue was performed. Despite preoperative imaging and good feasibility of TAVR after Ozaki, temporary obstruction of the right coronary artery occurred after TAVR, which was successfully resolved by ostial stent implantation. DISCUSSION: Published reports on TAVR after Ozaki are sparse, especially in patients with rare multisystem disorders such as Alagille syndrome. TAKE-HOME MESSAGE: TAVR after Ozaki in patients with Alagille syndrome can be successfully performed by a multidisciplinary heart team with special care regarding potential coronary occlusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.